The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors
The biotech markets of early 2026 have become a theater of the extreme, where the…
market opportunities
Unmet Opportunities: Analyzing the FDA List of Drugs Without Approved Generics
The FDA’s Off-Patent, Off-Exclusivity Drugs without an Approved Generic list highlights pharmaceutical products that are…